Published May 3, 2021, 12:22 PM
The Department of Science and Technology-Philippine Council for Health Research and Development (DOST-PCHRD) said on Monday, May 3, that the clinical trial on the use of Ivermectin as a treatment for coronavirus disease (COVID-19) will involve patients with “non-severe” or those with mild to moderate cases.
DOST-PCHRD Executive Director Dr. Jaime C. Montoya (Manila Bulletin File Photo)
DOST-PCHRD Executive Director Dr. Jaime C. Montoya said the research team from the University of the Philippines (UP) Manila- Philippine General Hospital (PGH), headed by Dr. Aileen Wang, is now drafting the research protocol, which includes the timeline of the clinical trial and the target participants.
Published May 3, 2021, 6:25 PM
Clinical trials on the use of the Virgin Coconut Oil (VCO), lagundi (Chinese chaste tree), and tawa-tawa (Euphorbia hirta) as a coronavirus disease (COVID-19) therapeutic or supplement are expected to be completed by June, the Department of Science and Technology-Philippine Council for Health Research and Development (DOST-PCHRD) said on Monday, May 3.
(Manila Bulletin File Photos)
DOST-PCHRD Executive Director Dr. Jaime C. Montoya expressed optimism that studies on the herbal medicines as a potential supplement that could help prevent the worsening of condition in patients afflicted with the COVID-19 virus will be concluded next month.
“Itong lagundi, tawa-tawa at VCO, sana ay matapos na at ang target po natin ay katapusan ng Hunyo, pero po maraming pag-aaral na nagsisimula rin na bago na iba ibang indikasyon ang tinintingan so maaari na magoverlap (These clinical trials on lagundi, tawa-tawa and VCO, hopefully, they will be completed soon, an
Enhanced Nutribun (Manila Bulletin File Photo)
DOST-PCHRD Executive Director Dr. Jaime C. Montoya cited the readiness of the technology adopters of numerous nutritious food products of the Food and Nutrition Research Institute (DOST-FNRI) to launch such kind of food distribution drive.
“Tingin ko po naman ay posible pong mangyari yan dahil gusto nating makinabang ang ating mga kabayaan at ang ‘yung mga adopters natin ay willing naman po magsagawa ng ganitong pamimigay din [sa] ating kababayan ng nutribun (I think it is possible for that to happen because we want our countrymen to benefit and our adopters are willing to conduct this kind of distribution of nutribun to our people),” he said in a public briefing.
Published May 3, 2021, 1:13 PM
The clinical trial results on the use of anti-parasitic drug Ivermectin as a treatment for coronavirus disease (COVID-19) could be expected by January 2022 or by first quarter of 2022, a top official of the Department of Science and Technology-Philippine Council for Health Research and Development (DOST-PCHRD) said Monday, May 3.
(Manila Bulletin File Photo)
DOST-PCHRD Executive Director Dr. Jaime C. Montoya said preparations were underway to ensure the smooth conduct of the clinical trial, which will likely be conducted by end of May or first week of June.
DOST-PCHRD Executive Director Dr. Jaime C. Montoya says results of Ivermectin clinical trial may be out by first quarter of 2022.@manilabulletin charissa luci (@chailuci) May 3, 2021
Results of ivermectin clinical trial out by Q1 2022 cnnphilippines.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from cnnphilippines.com Daily Mail and Mail on Sunday newspapers.